biostudies-literatureUnknown6Calvo AC<h4>Background</h4>Amyotrophic lateral sclerosis (ALS) is one of the most devastating neurodegenerative diseases. Neurotrophic factors have been widely tested to counteract neurodegenerative conditions, despite their unspecific neuronal access. The non-toxic C-terminal fragment of the tetanus toxin (TTC) heavy chain has been studied not only as a carrier molecule to the CNS but also as a neuroprotective agent. Because the neurotrophic effects of BDNF have been demonstrated in vitro and in vivo, the question addressed in this work is whether a fusion molecule of BDNF-TTC may have a synergistic effect and enhance the neuroprotective properties of TTC alone in a mouse model of ALS.<h4>Methods</h4>Recombinant plasmid constructs (pCMV-TTC and pCMV-BDNF-TTC) were injected into the quadriceps femOrphanet journal of rare diseases10https://www.ebi.ac.uk/biostudies/studies/S-EPMC3072305biostudies-literatureLack of a synergistic effect of a non-viral ALS gene therapy based on BDNF and a TTC fusion molecule.PMC3072305Moreno-Igoa MMunoz MJMancuso RCalvo ACNavarro XPenas CManzano ROsta ROlivan SZaragoza PfalseLack of a synergistic effect of a non-viral ALS gene therapy based on BDNF and a TTC fusion molecule.<h4>Background</h4>Amyotrophic lateral sclerosis (ALS) is one of the most devastating neurodegenerative diseases. Neurotrophic factors have been widely tested to counteract neurodegenerative conditions, despite their unspecific neuronal access. The non-toxic C-terminal fragment of the tetanus toxin (TTC) heavy chain has been studied not only as a carrier molecule to the CNS but also as a neuroprotective agent. Because the neurotrophic effects of BDNF have been demonstrated in vitro and in vivo, the question addressed in this work is whether a fusion molecule of BDNF-TTC may have a synergistic effect and enhance the neuroprotective properties of TTC alone in a mouse model of ALS.<h4>Methods</h4>Recombinant plasmid constructs (pCMV-TTC and pCMV-BDNF-TTC) were injected into the quadriceps fem2011-01-01T00:00:00Z2011 Mar2025-04-20T02:20:31.11Z2021-02-20T00:53:54ZS-EPMC30723052141861910.1186/1750-1172-6-10